Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,730,000 | 2,152,300 | 1,937,200 | 3,916,300 | 3,105,900 |
| Marketable Securities | 8,114,800 | 7,761,300 | 6,990,500 | 5,043,400 | 4,636,400 |
| Receivables | 5,667,300 | 5,584,500 | 5,121,300 | 5,118,600 | 5,328,700 |
| Inventories | 2,580,500 | 2,562,000 | 2,507,700 | 2,424,700 | 2,401,900 |
| TOTAL | $19,479,200 | $18,634,800 | $16,923,000 | $16,909,200 | $15,884,100 |
| Non-Current Assets | |||||
| PPE Net | 4,146,400 | 4,006,100 | 3,922,600 | 3,880,900 | 3,763,000 |
| Investments And Advances | 5,396,500 | 5,778,500 | 6,327,200 | 6,066,600 | 6,591,800 |
| Intangibles | 1,038,600 | 1,017,200 | 953,000 | 928,700 | 915,500 |
| Other Non-Current Assets | 3,019,500 | 2,726,700 | 2,531,700 | 2,274,500 | 2,060,100 |
| TOTAL | $13,601,000 | $13,528,500 | $13,734,500 | $13,150,700 | $13,330,400 |
| Total Assets | $33,080,200 | $32,163,300 | $30,657,500 | $30,059,900 | $29,214,500 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 606,600 | 536,600 | 547,300 | 599,500 | 589,200 |
| Other current liabilities | 2,357,900 | 2,644,700 | 2,176,000 | 2,074,300 | 2,074,200 |
| TOTAL | $3,423,400 | $3,598,600 | $3,104,400 | $3,100,100 | $3,141,300 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,982,900 | 1,982,600 | 1,982,200 | 1,981,800 | 1,981,400 |
| Deferred Revenues | 458,900 | 417,300 | 381,100 | 426,300 | 477,900 |
| Other Non-Current Liabilities | 854,100 | 832,400 | 716,800 | 677,300 | 638,000 |
| TOTAL | $3,683,700 | $3,660,300 | $3,535,200 | $3,464,600 | $3,409,200 |
| Total Liabilities | $7,107,100 | $7,258,900 | $6,639,600 | $6,564,700 | $6,550,500 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 109,762 | 108,947 | 108,559 | 109,710 | 109,326 |
| Common Shares | 100 | 100 | 100 | 100 | 100 |
| Retained earnings | 27,260,300 | 26,100,700 | 25,092,900 | 24,124,500 | 23,306,700 |
| Other shareholders' equity | -81,300 | -176,900 | -197,600 | -181,100 | -239,100 |
| TOTAL | $25,973,100 | $24,904,400 | $24,017,900 | $23,495,200 | $22,664,000 |
| Total Liabilities And Equity | $33,080,200 | $32,163,300 | $30,657,500 | $30,059,900 | $29,214,500 |